More about

Axial Spondyloarthritis

News
September 06, 2023
2 min read
Save

Early axial spondyloarthritis defined as a symptom duration of less than 2 years

Early axial spondyloarthritis defined as a symptom duration of less than 2 years

A new consensus definition for early axial spondyloarthritis indicates disease that has manifested symptoms for less than 2 years, according to a recommendation published in Annals of the Rheumatic Diseases.

News
August 18, 2023
6 min read
Save

Patients with undiagnosed psoriatic arthritis, axial SpA often ‘bounced’ around providers

Patients with undiagnosed psoriatic arthritis, axial SpA often ‘bounced’ around providers

Patients with axial spondyloarthritis and psoriatic arthritis routinely “bounce” from one provider to the next for years before finally receiving the correct diagnosis in a rheumatology clinic, according to experts.

News
June 08, 2023
1 min read
Save

Rheumatology patients with anxiety, depression demonstrate low self-management

Rheumatology patients with anxiety, depression demonstrate low self-management

Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.

News
May 31, 2023
2 min read
Save

Clinicians accept own opinion of low disease activity over T2T in axial spondyloarthritis

Clinicians accept own opinion of low disease activity over T2T in axial spondyloarthritis

In patients with residual axial spondyloarthritis disease activity, many physicians avoid strict adherence to treat-to-target guidelines in favor of low disease activity, based on their own opinion, as a treatment goal, according to data.

News
May 07, 2023
3 min read
Save

Lack of ‘good disease model’ inhibits treatment decision-making in axial spondyloarthritis

Lack of ‘good disease model’ inhibits treatment decision-making in axial spondyloarthritis

DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

News
April 03, 2023
2 min read
Save

Glucocorticoid use, male sex predict more severe COVID-19 in psoriatic disease, axial SpA

Glucocorticoid use, male sex predict more severe COVID-19 in psoriatic disease, axial SpA

Glucocorticoid use, older age, male sex and comorbidity burden are among the predictors of more severe COVID-19 in patients with psoriasis, psoriatic arthritis or axial spondyloarthritis, according to data.

News
March 22, 2023
2 min read
Save

Ixekizumab demonstrates no new safety concerns over 3 years in axial spondyloarthritis

Ixekizumab demonstrates no new safety concerns over 3 years in axial spondyloarthritis

An analysis of long-term ixekizumab use over 3 years in patients with axial spondyloarthritis found no new safety signals, according to data published in The Journal of Rheumatology.

News
March 20, 2023
2 min read
Save

Postpartum patients may be at risk for false-positive axial spondyloarthritis diagnosis

Postpartum patients may be at risk for false-positive axial spondyloarthritis diagnosis

As many as 41% of patients who are 1 year postpartum meet the ASAS criteria for sacroiliitis, which could lead to false positive diagnoses of axial spondyloarthritis, according to data published in Arthritis & Rheumatology.

News
February 28, 2023
2 min read
Save

‘A little bit unique’: Consider every SAPHO manifestation when examining patients

‘A little bit unique’: Consider every SAPHO manifestation when examining patients

SCOTTSDALE, Ariz. — SAPHO is complex, but knowing its potential manifestations can help clinicians identify and help patients, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician meeting.

News
February 23, 2023
2 min read
Save

One-quarter of patients with axial SpA remain flare-free after ceasing etanercept

One-quarter of patients with axial SpA remain flare-free after ceasing etanercept

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.

View more